Company Overview

Perimeter Medical Imaging AI, Inc. is a Canadian medical technology company focused on advanced imaging tools designed to improve real-time surgical decision-making. The company operates in the healthcare technology and medical imaging industries, with a primary emphasis on ultra-high-resolution optical coherence tomography (OCT) imaging systems used during cancer surgeries. Its flagship platform, the Perimeter S-Series OCT system, is designed to help surgeons visualize microscopic tissue structures in real time at the point of care, with the goal of reducing repeat surgeries caused by incomplete tumor removal.

The company’s principal revenue drivers are the commercialization and deployment of its intraoperative imaging systems, related consumables, and software capabilities incorporating artificial intelligence. Perimeter Medical Imaging AI primarily targets hospitals, surgical centers, oncologic surgeons, and pathology-related workflows, particularly in breast-conserving surgery. The company has positioned itself around providing imaging detail beyond conventional intraoperative assessment tools, combining OCT hardware with AI-assisted interpretation technologies. Founded in Canada and later expanding operationally into the United States, the company evolved from a medical imaging development business into a commercial-stage oncology-focused imaging company supported by clinical studies, regulatory clearances, and strategic healthcare partnerships.

Business Operations

Perimeter Medical Imaging AI conducts its operations through integrated imaging technology development, clinical validation, and commercialization activities. Its principal operating focus is the development and marketing of the Perimeter S-Series OCT platform and related AI-enabled imaging applications. Revenue generation is primarily tied to system placements, software integration, service arrangements, and future adoption of AI-enhanced diagnostic support tools. The company maintains operational and commercialization activities in both Canada and the United States, with a strong emphasis on the U.S. healthcare market due to the scale of surgical oncology procedures and reimbursement opportunities.

The company controls proprietary imaging technology combining high-resolution OCT hardware with machine-learning-based tissue analysis capabilities. Perimeter has also pursued clinical collaborations with major cancer treatment and research institutions to support validation and adoption of its technologies. Public disclosures and company filings reference collaborations and grant-supported initiatives connected to cancer imaging research, including support associated with U.S. federal cancer research programs. The company does not operate as a diversified conglomerate and remains focused primarily on surgical oncology imaging applications and related software development.

Strategic Position & Investments

Perimeter Medical Imaging AI’s strategic direction centers on expanding adoption of AI-assisted intraoperative imaging technologies intended to improve surgical margin assessment. The company has invested substantially in the development of artificial intelligence capabilities designed to identify suspicious tissue patterns during surgery, particularly for breast cancer procedures. Its strategy includes continued clinical validation, regulatory advancement, commercial scaling, and integration of imaging workflows into hospital surgical practices.

The company has also pursued growth through technology development initiatives and external funding support rather than through large-scale acquisitions. Publicly disclosed investments have focused on AI model development, imaging platform enhancement, and clinical studies intended to support commercialization and reimbursement pathways. Perimeter’s strategic positioning is tied to the broader trend toward precision medicine, real-time diagnostics, and AI-enabled surgical technologies. Data regarding material portfolio company investments or diversified subsidiary holdings is limited in publicly available filings, and broader investment activity outside its core imaging platform remains inconclusive based on available public sources.

Geographic Footprint

Perimeter Medical Imaging AI is headquartered in Toronto, Canada, while maintaining substantial operational activities in the United States, including commercialization, regulatory engagement, and clinical collaboration efforts. The company’s imaging systems and development initiatives are primarily directed toward the North American healthcare market, particularly U.S. hospitals and cancer treatment centers.

Its operational footprint includes clinical and commercial relationships across major medical institutions in North America, with strategic emphasis on expanding adoption in the U.S. surgical oncology market. While the company is publicly traded in Canada and accessible to international investors through over-the-counter market listings, publicly available disclosures indicate that its primary commercial influence remains concentrated in the United States and Canada rather than broad multinational operations across Europe, Asia, or Latin America.

Leadership & Governance

Perimeter Medical Imaging AI is led by executives with backgrounds in medical technology, healthcare commercialization, finance, and oncology-focused innovation. The company’s leadership strategy emphasizes advancing AI-enabled surgical imaging technologies through clinical evidence generation, regulatory engagement, and targeted commercialization in oncology care settings. Governance oversight is provided through its board structure and public company reporting obligations in Canada and U.S. market disclosures.

Key executives and leadership figures include:

• Adrian Mendes – Chief Executive Officer
• Tom Boon – Chief Financial Officer
• Jeremy Sobotta – Chief Operating Officer
• Dr. Jennifer Cotton – Senior Vice President, Clinical Affairs and Medical Affairs

The company’s leadership philosophy, as reflected in public filings and investor communications, focuses on improving surgical outcomes through real-time imaging innovation, evidence-based clinical adoption, and integration of artificial intelligence into intraoperative decision support systems.